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Black Americans are diagnosed with schizophrenia spectrum disorders at more than 
twice the rate of White individuals and experience significantly worse outcomes following the 
diagnostic event. Yet, little research to date has attempted to understand what specific factors 
contribute to worse functional outcomes among Black Americans with schizophrenia. The 
current study aims to broaden the current literature on such racial differences in functioning by 
using data from a double-blind, randomized treatment study to (1) examine baseline racial 
differences in established predictors of functioning (i.e., neurocognition, social cognition, and 
symptom severity); (2) investigate whether race moderates the strength of the relationship 
between these predictors and functioning at baseline; and (3) explore whether there are racial 
differences in the effectiveness of a novel psychopharmacological intervention of intranasal 
oxytocin in improving functioning among Black and White individuals with schizophrenia. 
Results revealed a significant difference in neurocognition at baseline as measured by the 
RBANS, with Black participants performing more poorly than White participants. No racial 
differences in measures of social cognition or symptom severity were observed. In addition, at 
baseline, race was found to moderate the relationship between PANSS-rated general symptoms 
and functioning measured by the SLOF but did not influence the relationship between 
other impact of oxytocin on functioning, social cognition, and symptom severity. Implications of 
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these findings and suggestions for future work aimed at understanding racial disparities in 
functioning among Black and White Americans with schizophrenia are discussed. Implications 
of these findings and suggestions for future work aimed at understanding racial disparities in 
functioning among Black and White Americans with schizophrenia are discussed. 
vi 
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 Black Americans are diagnosed with schizophrenia spectrum disorders at more than 
twice the rate of White individuals (Olbert, Nagendra, & Buck, 2018 ; Schwartz & Blankenship, 
2014). After diagnosis, Black individuals fare worse than their White counterparts in various 
indices of functioning (Eack & Newhill, 2012). Given the systemic and structural inequality that 
disadvantages both Black individuals and individuals with mental illness (Lewis, Cogburn, & 
Williams, 2015 ; McGuire & Miranda, 2008 ; Merritt-Davis & Keshavan, 2006 ; D. R. Williams, 
Yan Yu, Jackson, & Anderson, 1997), it is understandable that Black individuals’ experience 
with this disorder may differ from White individuals in several domains. Such racial disparities 
are evidenced by greater number hospitalizations (Eack & Newhill, 2012), higher rates of 
incarceration (Baillargeon, Binswanger, Penn, Williams, & Murray, 2009 ; Prince, Akincigil, & 
Bromet, 2007), homelessness (Folsom et al., 2005 ; Nagendra, Schooler, et al., 2018), and 
decreased employment rates (Rosenheck et al., 2006) for Black individuals with schizophrenia 
compared to White individuals with schizophrenia. Unfortunately, little research has attempted 
to understand what specific factors contribute to these poorer outcomes for Black individuals 
with schizophrenia. As such, the need for research in this area is long overdue.  
Racial Differences in Predictors of Functioning 
One way to better understand the factors contributing to these racial disparities is to 
examine factors that predict functional outcomes in this population. Numerous studies have 
shown that neurocognition, social cognition, and symptom severity are among the strongest 
predictors of functioning in schizophrenia 
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(Fervaha, Foussias, Agid, & Remington, 2014 ; Fett et al., 2011 ; Halverson, Orleans-
Pobee, et al., 2019 ; Rabinowitz et al., 2012 ; Shamsi et al., 2011). Additionally, a small number 
of studies have documented racial differences in these domains. Specifically, in two studies of 
nationally- representative samples of individuals with schizophrenia, Black individuals 
performed worse on neurocognitive assessment batteries compared to White individuals, even 
when controlling for patient education and other sociodemographic factors (Keefe et al., 2006 ; 
Nagendra, Schooler, et al., 2018).  Black individuals also tend to perform worse on social 
cognitive assessments, particularly tasks evaluating emotion perception and theory of mind 
abilities (Brekke, Nakagami, Kee, & Green, 2005 ; Pinkham, Kelsven, Kouros, Harvey, & Penn, 
2017). Studies demonstrating differences in symptom severity are perhaps the most prevalent, 
with some suggesting higher prevalence rates of positive symptoms among Black individuals 
compared to Whites (Adebimpe, Klein, & Fried, 1981 ; Barrio et al., 2003 ; Chu, Sallach, 
Zakeria, & Klein, 1985 ; Nagendra, Schooler, et al., 2018), and others indicating more negative 
symptoms among White individuals compared to Blacks (Fabrega, Mezzich, & Ulrich, 1988). 
Taken together, these studies provide some evidence that racial disparities exist among important 
predictors of functioning in schizophrenia.  
Despite these initial studies documenting racial differences in predictors of functioning, 
work in this area is still quite limited. Indeed, a systematic review by Nagendra et al. (2020) 
found that among 474 studies on schizophrenia published between 2014-2016 in top psychiatric 
journals, only nine percent of these studies included primary analyses by race (i.e., investigated 
racial differences in primary outcomes of the study). Further, this review, along with its 
predecessors by Lewine et al. (1999) and Chakraborty and Steinhaur (2010), indicates that many 
schizophrenia studies treat racial differences as something to be controlled for (i.e., a nuisance 
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variable) rather than investigating them as meaningful differences to be addressed (Nagendra, 
Orleans-Pobee, et al., 2020). As such, further research focused on exploring meaningful racial 
disparities in domains related to functioning is certainly needed.   
In addition to better understanding racial disparities in critical predictors of functioning, it 
may also be useful explore how the strength of the association between these predictors and 
functioning vary by race. Indeed, a few studies have offered preliminary evidence that race 
moderates the relationship between some of these predictors and functional outcomes in 
schizophrenia. For example, supplemental analyses from the Halverson et al. (2019) meta-
analysis indicated that more racially diverse samples showed weaker relationships between 
neurocognition and functional outcomes. In contrast, findings from a meta-analysis conducted by 
Irani et al. (2012) revealed that more racially homogenous samples (e.g., higher percentage of 
White individuals) had weaker associations between emotion perception – a domain of social 
cognition – and functional outcomes. With the exception of these two studies, research 
investigating how race moderates the relationship between established predictors of functioning 
in schizophrenia is practically non-existent. Yet, the findings of Halverson et al. (2019) and Irani 
et al. (2012) crucially suggest that race may moderate the links between these predictors and 
functioning, thus indicating a need to investigate the strength of these predictors across racial 
lines. Importantly, an investigation of racial differences in these predictive relationships would 
contribute to the current literature by identifying more relevant treatment targets (i.e., factors that 
are better predictors of functioning for Black individuals) and offering further insight into the 





Racial Differences in Treatment Effectiveness  
In addition to examining predictors of functioning, another way to enhance understanding 
of racial disparities in schizophrenia is to examine racial differences in the effectiveness of 
interventions designed to improve functioning. Currently, a majority of studies investigating 
racial differences in treatment of schizophrenia are limited to describing differences in the types 
of treatments prescribed  (Chien, 2008 ; Kreyenbuhl, Zito, Buchanan, Soeken, & Lehman, 2003 ; 
Kuno & Rothbard, 2002 ; Nagendra, Schooler, et al., 2018) or level of treatment engagement 
(Oluwoye et al., 2018). Indeed, only a few studies have examined differences in the actual 
effectiveness of treatments between Black and White individuals (Emsley et al., 2002). Thus, it is 
unclear whether existing treatments are actually helpful in improving racial disparities in 
functioning.  Given that several treatments are designed to either target the predictors described 
above or directly intervene on functioning, examining racial differences in the effectiveness of 
such treatments may be useful in identifying interventions that are better suited for addressing 
racial disparities in schizophrenia.  
One potential intervention worthy of investigating racial differences in effectiveness is a 
novel psychopharmacological intervention, intranasal oxytocin is a neuropeptide associated with 
a host of psychological effects in both animals and humans, including increased positive social 
behavior and antipsychotic-like outcomes  (Macdonald & Macdonald, 2010 ; Pedersen et al., 
2011). The focus on intranasal oxytocin in the present study is motivated by several factors. 
First, many interventions for schizophrenia aimed at improving functioning often do so through 
social skills training (Kurtz & Mueser, 2008 ; Mueser, Deavers, Penn, & Cassisi, 2013), and 
while such training can be effective in improving functioning, it is also a time-intensive 
intervention. On the other hand, acute intranasal oxytocin administration has been found to 
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increase oxytocin concentrations in the brain (Born et al., 2002) and is associated with 
improvements in domains targeted by social skills training such as increased in positive social 
behavior (e.g., interpersonal trust, eye gaze) and improved social cognition (Davis et al., 2014 ; 
Macdonald & Macdonald, 2010 ; Pedersen et al., 2011). As such, oxytocin may be a promising 
alternative intervention that targets social deficits to improve functioning while also reducing the 
need for time-intensive skills training. Notably, this is kind of intervention could be particularly 
useful for Black individuals given research suggesting less treatment engagement and higher 
attrition among Black patients in long-term psychosocial treatments (Maura & Weisman de 
Mamani, 2017 ; Oluwoye et al., 2018).  
Further, oxytocin has also been linked with enhanced stress regulation (Grimm et al., 
2014 ; Olff et al., 2013). Both psychosocial and biological responses to stress can have critical 
impacts on the pathogenesis and maintanence of psychosis (Anglin et al., 2021 ; Berger et al., 
2018 ; Corcoran et al., 2003).  Thus, researchers have suggested that oxytocin is a promising 
therapeutic intervention for alleviating psychiatric symptoms associated with dysregulated stress 
reactivity (Martins et al., 2020 ; Olff et al., 2013). Along these lines, race-related stress (i.e., 
experiences of racism and/or discrimination) is a unique stressor experienced by members of 
marginalized racial/ethnic groups, especially Black Americans (Brown, Mitchell, & Ailshire, 
2020 ; Clark, Anderson, Clark, & Williams, 1999 ; Goosby, Cheadle, & Mitchell, 2018). It is 
possible that experiences of race-related stress may be contributing to differences in outcomes 
between Black and White Americans with schizophrenia given the links between stress and the 
maintenance of psychopathology (Anglin et al., 2021 ; Berger et al., 2018). As such, treatments 
that directly intervene on stress regulation may have particular importance for Black Americans 
with schizophrenia. Though this study is unable to directly explore the impact of oxytocin on 
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stress regulation, an exploration of racial differences in the effects of oxytocin may offer initial 
insight into whether interventions targeting biological mechanisms of stress reactivity might be 
especially useful for Black Americans with schizophrenia.  
Finally, while some studies have found ameliorative effects of intranasal oxytocin such as 
reduced psychotic symptoms and  improved social cognition and stress regulation (Davis et al., 
2014 ; Gibson et al., 2014 ; Olff et al., 2013 ; Pedersen et al., 2011), other studies have found 
marginal or null effects (Halverson, Jarskog, Pedersen, & Penn, 2019 ; Jarskog et al., 2017 ; D. 
Williams & Bürkner, 2017), thus indicating some inconsistency of this intervention. Indeed, 
using the same data that will be analyzed in this current study, Jarskog et al., (2017) previously 
found limited effects of oxytocin in improving functioning and some factors associated with 
functioning (i.e., negative symptoms), yet no effect on other correlates of functioning (i.e., social 
cognition). These mixed findings, along with the lack of previous research on racial differences 
in the effects of this intervention, suggest the need to investigate whether the effects of intranasal 
oxytocin on functioning may vary as a result of race among individuals with schizophrenia.  
Aims of the Present Study  
The present study seeks to examine potential contributors to the observed racial 
disparities in functioning between Black and White individuals with schizophrenia. To do so, we 
aim to (1) assess baseline racial differences in established predictors of functioning, including 
neurocognition, social cognition, and symptom severity among Black and White individuals with 
schizophrenia; and (2) examine whether race moderates the strength of the relationship between 
these predictors and functioning; (3a) investigate whether there are racial differences in the 
effectiveness of a novel psychopharmacological intervention of intranasal oxytocin in improving 
functioning; and (3b) in investigate whether there are racial differences in the effectiveness 
 
 7 
intranasal oxytocin in improving secondary outcomes associated with functioning, specifically 
social cognition and symptom severity.  
Hypotheses 
 It is hypothesized that significant racial differences will exist in predictors of functioning 
in schizophrenia between Black and White participants. Specifically, it is expected that Black 
participants will demonstrate worse performance on measures of neurocognition and social 
cognition compared to White individuals. It also expected that racial differences will exist in 
symptom severity.  However, given the variety in symptom domains and mixed findings in 
existing literature in this area, specific predictions about the directionality of these differences 
are difficult to make.  
  (a) It is hypothesized that neurocognition, social cognition, and symptom severity will 
each independently predict participants’ level of functioning and (b) the strength of the 
predictive relationship between these factors and functioning will be moderated by participants’ 
race. Of note, aim 2b will be exploratory as it is not possible to make empirically supported 
predictions about the direction of this moderation at the moment.  No specific hypotheses are 
being made for aim 3a or 3b as these are exploratory objectives of this study designed to 





Participants and Study Design 
Data for this study comes from a larger double-blind, randomized treatment study 
conducted between June 2011 and September 2014, thus all data collection has been completed 
(NCT GOV Trial Number: NCT01394471). Primary findings of this treatment study are detailed 
in Jarskog et al. (2017). Additional exploratory outcomes are also detailed in Halverson et al. 
(2019).  Eligibility criteria included: 18–65 years of age; diagnosed with schizophrenia or 
schizoaffective  disorder as determined by the Structured Clinical Interview for the Diagnostic 
and  Statistical Manual of Mental Disorders, 4th edition; duration of illness was greater than one 
year; clinically stable outpatient status and receiving antipsychotic medication with no change in 
antipsychotic agents or dose for one month prior to entry; concomitant medications were  
permitted (except as noted in exclusion criteria) if doses were unchanged for one month  prior to 
entry. Women of childbearing potential had to use an acceptable method of birth-control. 
Further, to ensure participants were functioning at a deficit level relative to a normative 
sample on primary outcome measures, participants had to score below a 24 on Reading the Mind 
in the Eyes Test (a theory of mind task; see below for details about this measure). This cutoff 
score was selected because a score below 24 is 0.5 standard deviation (SD) below the mean in a 
large normative sample.  If participants scored above this cutoff on the Eyes Test, then they had 
to have a score of three or greater on the Positive and Negative Syndrome Scale (PANSS) items: 
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suspiciousness/persecution, hostility, passive/apathetic social withdrawal, 
uncooperativeness, active social avoidance in order to be eligible. All subjects provided written 
informed consent.   
Exclusion criteria were as follows: Manic or hypomanic episode within the past 2 years 
for subjects with schizoaffective disorder; alcohol or substance abuse or dependence in the past 3 
months (except caffeine or nicotine); simulant or chronic glucocorticoid use; unstable serious 
medical illness; major surgery/trauma in the past 4 months; pregnancy, childbirth in the past 6 
months, or breast-feeding in the past 3 months; <5th grade reading level on the Wide Range 
Achievement Test (WRAT). 
While a total of 68 individuals were included in the initial study of Jarskog et al., (2017), 
the current study included 66 individuals (31 Black; 48 male), as two participants identified as a 
race other than White or Black. All participants had a diagnosis of schizophrenia or 
schizoaffective disorder. Participants completed screening, baseline, and assessment visits at six 
and 12 weeks.  Participants were randomized to twice-daily intranasal oxytocin or placebo 
stratified by sex and total PANSS score. See CONSORT diagram adapted from Jarskog et al. 
(2017).  
Intervention  
Participants remained on their pre-study medications and doses over the course of the 
study.  Intranasal study drug was self-administered twice daily (before breakfast and before 
dinner) for 12 weeks. Participants were trained on how to administer the spray prior to baseline 
and administration was also observed for accuracy at 2 and 6 weeks. Each dose consisted of six 
0.1 mL insufflations (alternating every 30 seconds between the left and right nostril); each dose 
was approximately 24 international units of oxytocin (Syntocinon Spray, Novartis) or placebo 
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(containing all ingredients in Syntocinon Spray except oxytocin). This dose was selected based 
on efficacy in previous pilot studies (Gibson et al., 2014; Pedersen et al., 2011). Bottles 
containing study drug (50 mL solution) were weighed before dispensing to subjects and upon 
return. Bottle weights and a daily medication diary were used to assess drug adherence. 
Measures  
Symptom Severity 
 Symptom severity was assessed via the Positive and Negative Syndrome Scale (PANSS), a 
thirty-item measure of positive and negative symptoms of schizophrenia (Kay, Fiszbein, & 
Opler, 1987). Items were scored by a trained assessor on a scale from 1 (asymptomatic) to 7 
(extremely symptomatic) via structured clinical interview and behavioral observations. Severity 
of symptoms was thus indexed by total scores for Positive, Negative, and General Symptom 
Subscales. The PANSS was administered at baseline, six, and 12 weeks.  
Neurocognition 
Neurocognition was assessed using the Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS). The RBANS consists of 12 subtests that were used to 
calculate five index scores: Immediate Memory, Visuospatial/Constructional, Language, 
Attention, and Delayed Memory. Index scores were age adjusted and standardized such that the 
normal mean was equal to 100 with an SD of 15, based on a normative sample (Randolph, 
Tierney, Mohr, & Chase, 1998). The index scores were combined to form the total score, a 
summary measure of RBANS performance. This battery has demonstrated solid psychometric 
properties for testing neurocognitive abilities of individuals with schizophrenia (Chianetta, 




Social cognition was assessed using a variety of measures that included both skills-based 
tasks and bias-oriented tasks. Skills-based tasks measure coordinated processing and assessment 
of external social situations. Further, skills-based tasks assess correct interpretation of such social 
situations, and thus have right or wrong answers. In contrast, bias-oriented tasks have no right or 
wrong answers, but rather assess individuals’ automatic interpretation of imagined interpersonal 
scenarios and examine patterns in such interpretations to identify social cognitive biases (Buck, 
Pinkham, Harvey, & Penn, 2016).  Social cognitive assessments were conducted at baseline, six, 
and 12 weeks.  
Skills-Based SC Measures.  
The Eyes Task. The Reading the Mind in the Eyes Task (Eyes Task, Baron-Cohen et al., 
2001 ) is a measure of theory of mind that requires participants to rapidly determine the mental 
state of another individual based solely on the eye regions of 36 different faces one by one on a 
computer. Participants are asked to select the most fitting mental state from four possible options 
that are listed on the screen along with the eye image (i.e., “irritated”, “joking”, “flirtatious”, 
“pensive”). Of note, all images are eyes of White faces. Performance is indexed by the total 
number correct. Possible scores range from 0-36. Comprehensive evaluation of the reliability and 
validity of this task has demonstrated sound psychometric properties, and it is considered a gold-
standard measure of social cognition in schizophrenia (Browne et al., 2016 ; Pinkham et al., 
2014 ; Pinkham, Harvey, & Penn, 2018). 
 ER-40. The Penn Emotion Recognition Task (ER-40; Kohler et al., 2003) assesses 
emotion perception abilities. Participants must correctly identify what type of emotional 
expression (Happy, Sad, Anger, Fear, or No Emotion) is being displayed for 40 different colored 
photos of faces that are balanced for age, sex, and race. For each emotion, 4 of the pictures are 
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high intensity and 4 are low intensity. Performance is indexed by the total number of correctly 
identified emotions, with possible scores ranging from 0 to 40. The ER-40 is also considered a 
gold-standard measure of social cognition in schizophrenia with sound psychometric properties  
(Browne et al., 2016 ; Pinkham et al., 2014, 2018). 
IPT-15. The Interpersonal Perception Task (IPT-15; Costanzo & Archer, 1989 ) is a 
measure of social perception processes. The measure consists of 15 video clips of common social 
interactions between 1-4 persons of diverse age, race, and gender groups. Each video clip is 
followed by a multiple choice question about the status of persons in the video (e.g., “who won 
the game?”), the accuracy of statements made about persons in the video (e.g., “which was the 
truth: the first or the second statement?”), or the level of intimacy between the persons in the 
video (e.g., how long have two in the video been dating, two weeks or two years?”). 
Performance was indexed via total number of accurate responses; thus, scores could range from 
0-15.  
Bias-oriented Measures.  
AIHQ. The Ambiguous Intentions Hostility Questionnaire (Combs, Penn, Wicher, & 
Waldheter, 2007) includes five second-person vignettes describing negative social situations 
with ambiguous causes (e.g., “you are walking by a group of young people who laugh as you 
pass by”). After reading the vignettes, participants are asked to rate the following on Likert 
scales: the intentionality of the other’s action, how angry it would make the participant feel, and 
how much he or she would blame the other. Responses to each item are averaged across scenario 
and summed to create an overall ‘blame score.’ Total scores range from 3 to 16 with higher 
scores indicating greater blame. Based on psychometric analysis, this tasks has been supported as 
a gold-standard for measuring social cognitive biases in schizophrenia (Buck et al., 2016).  
 
 13 
Trustworthiness Task. The Trustworthiness Task (Adolphs, Tranel, & Damasio, 1998) is 
an assessment of participants’ immediate social judgements about the trustworthiness of a range 
of people from diverse gender and ethnic backgrounds presented via photographs. Participants 
rate trustworthiness of each individual presented on a scale of -3 (strongly distrust) to 3 (strongly 
trust). Scores range from -126 to 126, with lower scores indicating greater bias toward distrusting 
others. Based on psychometric analysis, this tasks has also been supported as a gold-standard for 
measuring social cognitive biases in schizophrenia (Buck et al., 2016).  
Functioning   
Social functioning will be assessed using two different assessments, which were 
administered at baseline and 12 weeks.  
SLOF. The Specific Levels of Functioning Scale (SLOF; Harvey et al., 2011 ) assesses 
functioning of individuals across multiple domains. The SLOF is a 30-item, five point, informant 
and self-rated scale of a participant’s behavior and functioning in four areas: interpersonal 
relationships (e.g., initiating, accepting, and maintaining social contacts, effective 
communication), social acceptability (e.g., verbal and physical abuse, repetitive behaviors), 
participation in community activities (e.g., shopping, using the telephone, paying bills, use of 
leisure time, public transportation), and work skills (e.g., employable skills, punctuality, level of 
supervision needed). Performance was indexed by participant’s total scores as rated by 
themselves and their informant on the 30-item scale. 
SSPA. The Social Skills Performance Assessment (SSPA; Patterson et al., 2001 ) 
assesses competence in social functioning via roleplays. Due to the aims of the original study 
(Jarskog et al., 2017), only a modified version of the SSPA was administered to participants. 
Specifically, the modified SSPA consists of two 90-second roleplays. The first roleplay is an 
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unstructured conversation in which the research confederate plays the role of a new neighbor 
with whom the subject is instructed to strike up a conversation. In the second roleplay, the 
research confederate plays an upset friend with whom the subject is instructed to attempt to 
console. The roleplays are recorded and later rated on the following factors: Verbal social skill 
(e.g., content, clarity, fluency, asks questions), nonverbal social skill (e.g., gaze, involvement, 
meshing, appropriate affect, flat affect), and global social skill (e.g., social anxiety and overall 
social skill). Raters were trained to reliability by first watching several roleplays (from a 
previous study that used the same assessment) together with an advanced doctoral student, 
discussing their ratings and coming to a consensus. They then rated 20 role-plays on their own 
and reliability was calculated. Once they attained acceptable reliability (ICCs N 0.6), they were 
permitted to rate the roleplays from this study. Interrater reliability was calculated on the ratings 
of the first 39 videos of the schizophrenia sample completed by the coders; ICCs for all items 
were above 0.7 with the exception of Appropriate Affect (0.654). As such, performance was 
indexed via total ratings on each factor, which ranged from 1 to 5. Higher ratings indicate better 
social competence.   
Statistical Analysis   
 Aim 1: Racial Differences in Predictors of Functioning 
 To assess baseline racial differences in predictors of functioning: neurocognition, social 
cognition, and symptom severity, univariate analyses of covariance (ANCOVA) and multivariate 
analyses of variance (MANOVA) were used. Specifically, for assessing differences in 
neurocognition, a one-way ANCOVA was conducted to compare differences in RBANS scores 
by race while controlling for education. To assess differences in social cognition, a composite 
score for skills-based social cognition tasks was created by calculating z-scores for each task and 
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computing the mean for the Eyes, ER-40, and IPT (Nagendra, Twery, et al., 2018).  For these 
three measures, the average ICC was .69, with confidence interval between .50 and .79, p < 
.0001. ICCs between the social cognition bias-oriented tasks revealed no correlation between the 
AIHQ and Trustworthiness tasks, thus a bias-oriented composite was not computed, and these 
measures were analyzed separately. The skill-based composite score was entered into a one-way 
ANCOVA to assess differences in social cognition skills-based tasks by race, controlling for 
education. The AIHQ and Trustworthiness Task were also separately entered into a one-way 
ANCOVA controlling for education. Finally, to assess racial differences in symptom severity a 
MANOVA was conducted with Positive, Negative, and General Symptom Subscales of the 
PANSS as the dependent variables and racial group as the independent variable. This analysis 
followed up with post hoc analyses adjusting for multiple comparisons via Bonferroni correction.  
Aim 2: Race as a Moderator of Functioning 
To examine whether race moderates the relationships between baseline predictors of 
functioning and baseline measures of functioning, a series of moderated multiple regression 
models was conducted. For each cognition and/or symptom variable (e.g., AIHQ, PANSS Total 
score), a regression model was fitted predicting baseline functioning (e.g., SLOF) from the 
predictor and the dichotomous variable of race.  An interaction term of predictorXrace (e.g., 
AIHQXrace) was then added as an additional independent variable to assess whether moderation 
occurred.   
Aim 3: Racial Differences in Oxytocin Treatment Effectiveness 
To explore racial differences in the effect of intranasal oxytocin on functioning and 
secondary outcomes associated with functioning (i.e., social cognition and symptom severity), 
longitudinal mixed models were used. In these models, change from baseline was the outcome, 
 
 16 
with treatment group, race, and time, treatmentXrace, treatmentXtime, timeXrace, 
treatmentXtimeXrace, and baseline score for the outcome as predictors. Models were estimated 
for each outcome measure. An unstructured covariance pattern was specified for each model to 
account for correlations within each individual’s responses across repeated measures. Change 
from baseline was estimated with least-squares mean. Imputation for missing data was not 
performed given a high degree of missingness and small sample size, which make model 
estimations unstable. For significant and trend-level findings, effect sizes were calculated using 
the quotient of least-squares mean and pooled standards deviation at baseline (i.e., Cohen’s d).  





Sociodemographic Characteristics  
 
Independent samples t-tests and chi-squares were used to analyze racial differences 
among demographic and symptom variables as summarized in Table 1. There were no 
significant differences between White and Black participants in age, gender, symptom onset age, 
duration of symptoms, nor history of substance abuse. However, there was a significant 
difference in years of education between White and Black participants, with White individuals 
(M = 13.66, SD = 1.99) completing more years of education compared to Black individuals (M = 
12.24, SD = 1.61), p < .05. Additionally, there were significant racial differences in diagnosis 
type (χ2 = 12.09, p < .01). A greater proportion of Black individuals received schizophrenia 
diagnoses (paranoid type and undifferentiated type) compared to White individuals. Conversely, 
a greater proportion of White individuals received schizoaffective diagnoses (depressed and 
bipolar) compared to Black individuals. Lastly, the racial difference in prior hospitalizations 
trended toward statistical significance with White individuals (M = 9.69. SD = 15.23) having a 
higher number of hospitalizations on average compared to Black individuals (M = 4.58, SD = 
3.58), p < .10. Given existing research demonstrating associations between education and our 
outcomes of interest (i.e., neurocognition and social cognition), education was entered as a 
covariate in subsequent analyses in which neurocognition or social cognition were outcomes.    
Racial Differences in Predictors of Functioning 
 
To assess differences in neurocognition, a one-way ANCOVA was conducted to compare 
differences in RBANS scores by race, controlling for education. White and Black participants 
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significantly differed in scores on the RBANS after controlling for education, F (1, 55) = 12.38, 
p < .001, with White participants scoring higher than Black participants. 
 A one-way ANCOVA was conducted to assess differences in social cognition skills-
based tasks by race, controlling for education. There were no significant differences between 
racial groups in skills-based social cognition when controlling for education, p > .10.  
In regard to social cognitive biases, there were no significant correlations between the 
AIHQ and Trustworthiness tasks, thus a bias-oriented composite was not computed, and these 
measures were analyzed separately. There were no significant differences between Black and 
White participants on the AIHQ nor Trustworthiness Task scores (ps > .10).  
 To assess racial differences in symptom severity, a one-way MANOVA was conducted 
with Total, Positive, Negative, and General Symptom Subscales of the PANSS as the dependent 
variables and racial group as the independent variable. There was a statistically significant 
difference in PANSS scores based on racial group, F (3, 60) = 3.07, p < .05, Wilk’s Λ = 0.87, 
partial η2 = 0.13. Post-hoc analyses revealed that the average scores on the PANSS positive 
symptom subscale trended toward statistical significance (p = .09), with Black participants 
having higher scores compared to Whites. However, no other significant differences between 
White and Black participants in baseline PANSS scores emerged. See Table 2 for a summary of 
racial group differences in symptom and cognition variables, including full report of adjusted 
means and standard error. Though this aim was focused on assessing racial differences in 
established predictors of functioning, racial differences in baseline measures of functioning are 
also included in Table 2.  
Race as a Moderator of Functioning  
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Prior to examining how race may act as a moderator, the relationship between 
neurocognition, social cognition, symptom severity and measures of functioning (i.e., informant 
and participant-rated SLOF and SSPA) were first evaluated via bivariate correlations as 
summarized in Table 3. In regard to neurocognition, there were no significant relationships 
observed between the RBANS and either of the functioning measures. In regard to social 
cognition, a significant negative relationship was observed between the AIHQ and the SLOF 
participant-rated scale, such that lower blame bias was associated with greater self-reported level 
of functioning. As for symptoms, significant negative relationships were also observed between 
the PANSS General and Total scales and the SLOF participant-rated scale. For both of these 
scales, lower ratings of symptoms were associated with higher self-reported level of functioning. 
Finally, a significant negative relationship was observed between PANSS General scale and the 
SLOF informant-rated scale, such that lower ratings of general symptoms was associated with 
higher informant-reported level of functioning (e.g., family member). No other significant 
relationships were observed between either SLOF participant-rated or informant-rated scales and 
the social cognition skills or other symptom variables. Additionally, no significant relationships 
were observed between the SSPA and any of the cognition or symptom variables (all ps > .10).  
For each of the significant relationships described above, linear regressions were run to 
test whether the cognition and symptoms variables significantly predicted the associated 
functioning outcome. In regard to social cognition, the AIHQ was a significant predictor of the 
SLOF-patient-rated scale such that lower blame bias predicted higher self-reported functioning, 
F (1, 58) = 5.92, R2 = .078, b = -0.722, SE = 0.28, p < .05. For the symptom variables, the 
PANSS Total scale significantly predicted self-reported level of functioning on the SLOF, with 
lower ratings of total symptoms predicting higher self-reported functioning, F (1, 58) = 10.76, R2 
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= .144, b = -.379, SE = 0.116), p < .01. Finally, the PANSS General scale significantly predicted 
both self-reported (F (1, 58) = 11.90, R2 = .158, p < .001) and informant-reported levels of 
functioning on the SLOF (F (1, 58) = 5.59, R2 = .105, p < .05). Lower ratings of general 
symptoms predicted higher levels of self-reported (b = -.724, SE = .210, p < .001) and informant-
reported functioning (b = -.716, SE = .303, p < .05).  
Moderated multiple regression models were created for each of the significant predictive 
relationships between cognition/symptom variables (i.e., AIHQ, PANSS Total and General 
scales) and functioning measures (i.e., informant and participant- rated SLOF) reported above. 
Race moderated the effect of PANSS general symptoms on informant-reported level of 
functioning, F (3, 36) = 5.02, ΔR2 = .103, p < .05. Specifically, there was a significant negative 
linear relationship between PANSS general symptoms and informant-reported level of 
functioning among White individuals, such that lower ratings of symptoms predicted higher 
functioning, (b = -1.29, SE = 0.389, p < .001); however, this relationship did not exist among 
Black individuals (b = .003, SE = 0.426, p = .99). Race did not moderate the relationship 
between any other cognition or symptom variables and functioning measures (for all ΔR2s, p > 
.05).  
To further explore the moderating role of race in the relationship between the PANSS 
general symptoms and the informant-rated SLOF, additional moderated regressions were 
conducted for the informant-rated SLOF subscales: Interpersonal Relationships, Social 
Acceptability, Activities, and Work Skills. Race moderated the relationship between the PANSS 
general symptoms and the Interpersonal Relationships subscale (F (3, 41) = 4.25, ΔR2 = .096, p < 
.05). This moderation followed a similar patten as was found with the overall informant-rated 
SLOF. Specifically, there was a significant negative linear relationship between PANSS general 
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symptoms and informant-reported level of functioning in interpersonal relationships among 
White individuals, such that lower ratings of symptoms predicted higher functioning in 
interpersonal relationships, (b = -.331, SE = .167, p < .001); however, this relationship did not 
exist among Black individuals (b = .176, SE = 0.181, p = .34). Race was not a moderator of the 
relationship between the PANSS general symptoms and any other subscales of the informant-
rated SLOF (for all ΔR2s, p > .05).   
Racial Differences in Oxytocin Treatment Effectiveness  
 Longitudinal mixed models were used to explore whether there were differences in the 
effect of intranasal oxytocin on functioning outcomes, social cognition, and symptom severity as 
a function of race. Among all functioning outcomes, there were no significant three-way 
interactions of treatmentXtimeXrace. In sum, there were no significant differences in the effect 
of treatment on functioning between Black and White participants across time (see Table 4).  
Among the social cognition variables, there was a significant three-way interaction of 
treatmentXtimeXrace, indicating a significant difference in the effect of treatment between Black 
and White participants on the IPT (p < .05, Cohen’s d = 1.04; see Table 5). The change from 
baseline to 12 weeks between oxytocin and placebo groups for Black participants was 
significantly different from the change observed between oxytocin and placebo groups for White 
participants at this time point. While Black participants did not demonstrate between-group 
differences on the IPT at 12 weeks, White participants did demonstrate a between-group 
difference on this measure that was bordering statistical significance (p = .06, Cohen’s d = -.60). 
Of note, this difference was trending in favor of the placebo group.  Thus, White participants in 
the placebo group demonstrated improvement from baseline on the IPT (Cohen’s d = .32), while 
White participants in the oxytocin group did not. 
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Among the PANSS scales, there was a significant three-way interaction of 
treatmentXtimeXrace, indicating a significant difference in the effect of treatment between Black 
and White participants on the PANSS positive symptom scale (p < .05, Cohen’s d = -.83; see 
Table 6). The change from baseline to 6 weeks between the oxytocin and placebo groups for 
Black participants was significantly different from the change observed between oxytocin and 
placebo groups for White participants at this time point. For Black participants, there was not a 
statistically significant between-group difference in positive symptoms, though there was a 
significant within-group improvement among Black participants in the oxytocin group. In 
contrast, for White participants, there was a significant between-group difference, such that the 
placebo group demonstrated statistically significant improvement of positive symptoms (p < .05, 
Cohens d = .24) while the oxytocin group did not. There were no significant treatment 
differences as function of race for any other outcome measures; however, within each racial 
group, some measures demonstrated between-group changes by treatment group and within-
group changes by treatment group.  Given that these two-way interactions were not directly 




This study conducted secondary data analysis on a double-blind, randomized treatment study 
to (1) examine baseline racial differences in established predictors of functioning (i.e., 
neurocognition, social cognition, and symptom severity); (2) investigate whether race moderated 
the strength of the relationship between these predictors and functioning; and (3) explore 
whether there were racial differences in the effects of intranasal oxytocin in improving 
functioning, social cognition, and symptom severity among Black and White individuals with 
schizophrenia. 
In regard to the first aim of this study, the hypothesis that significant racial differences would 
exist in established predictors of functioning between Black and White individuals at baseline 
was partially supported. Black participants demonstrated worse neurocognitive performance 
relative to White individuals, even when controlling for education. The present findings replicate 
previous studies showing that Black Americans with schizophrenia obtain lower scores on 
measures of neurocognition relative to Whites (Keefe et al., 2006 ; Nagendra, Halverson, et al., 
2020 ; Nagendra, Schooler, et al., 2018). A robust body of research in nonclinical populations 
has also demonstrated similar trends of racial disparities in cognitive assessments, and have 
suggested that these disparities may be due to bias in assessment instruments (Berry, Clark, & 
McClure, 2011) and structural factors like income inequality (Zahodne, Manly, Smith, Seeman, 
& Lachman, 2017).  
Conversely, there were no significant racial differences in social cognition. The lack of 
significant differences in social cognition contrasts with previous studies demonstrating racial 
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differences in this domain among individuals with schizophrenia (Brekke et al., 2005 ; Monette, 
Lysaker, & Minor, 2021 ; Pinkham et al., 2017). One reason for this null finding may be due to 
how social cognition was measured in the present study. In an effort to reduce Type 1 errors 
associated with multiple comparisons, a social cognition skills composite score was created for 
participants that was comprised of scores on the Eyes Task, the ER-40, and the IPT. Previous 
studies looking at racial differences in social cognition focused on single measures of social 
cognition, thus the use of a composite score may have obscured significant group differences.  
Additionally, no significant differences were observed among the symptom variables, with 
the exception of a trend-level difference in PANSS positive symptoms (i.e., Black participants 
being rated as having higher positive symptoms relative to Whites). Again, these insignificant 
results may be explained by the method of measuring symptoms used in the current study. 
Though previous studies have found Black/White differences in symptom severity, they have 
utilized different procedures for assessing symptoms. For example, some studies have used item 
level analysis of individual PANSS items (Barrio et al., 2003 ; Monette et al., 2021) , while 
others have used a five-factor model of the PANSS items to characterize  symptoms (Nagendra, 
Schooler, et al., 2018). Moreover, other studies have used alternative instruments other than the 
PANSS to assess racial differences in symptoms (Adebimpe et al., 1981 ; Chu et al., 1985 ; 
Fabrega et al., 1988). The present study utilized the PANSS in its traditional form by assessing 
differences in total symptoms and the three subscales of positive, negative, and general 
symptoms, which may have contributed to the difference between the current findings and prior 
studies. 
Another possible explanation for the null findings may be related to the inclusion criteria for 
the study. To ensure that individuals were functioning at a deficit level relative to a normative 
 
 25 
sample, participants enrolled in this study had to score below a 24 on the Eyes Task (0.5 standard 
deviation below the mean in a large normative sample). If participants scored above this cutoff 
on the Eyes Test, then they had to have a score of three or greater on the following PANSS 
items: suspiciousness/persecution, hostility, passive/apathetic social withdrawal, 
uncooperativeness, active social avoidance in order to be eligible to participant in the study. As 
such, this study selected for participants that performed at relatively similar deficit levels on 
these measures. This may have subsequently reduced the amount of variation across racial 
groups. That said, it is also possible that the lack of significant racial differences in these known 
predictors of functioning (i.e., social cognition and symptom severity) indicates that other 
domains should be considered in exploring predictors relevant for understanding racial 
disparities in functional outcomes.  
One domain that may be relevant for understanding racial disparities in functioning may lie 
in socioeconomic status (SES). Indeed, past studies of individuals with schizophrenia have 
established significant overlap between being Black and being of lower socioeconomic status 
(Nagendra, Schooler, et al., 2018 ; Rosenheck et al., 2006). Further significant associations have 
been found between SES, predictors of functioning, and real-world outcomes among individuals 
with schizophrenia. For example, SES has been found to partially mediate the relationship 
between race and neurocognition (Nagendra, Halverson, et al., 2020) and has been associated 
with greater risk for hospitalizations and reduced well-being in schizophrenia samples (Goldberg 
et al., 2011). Though the present analyses controlled for education level – a domain sometimes 
used to index SES – the current dataset did not include other commonly used indicators of SES 
such as income, occupational status, or poverty status (Diemer, Mistry, Wadsworth, López, & 
Reimers, 2013) that would allow for more sensitive exploration of SES differences by race. As 
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such, future work should explore the nuanced interplay between race and SES in effort to better 
understand racial disparities in functioning in schizophrenia.  
 In addition to SES, another domain that has received relatively little attention in existing 
research on racial disparities in schizophrenia, is stress exposure. While a robust literature exists 
describing the role of stress exposure in the etiology of schizophrenia (Corcoran et al., 2003 ; 
Norman & Malla, 1993 ; Walker, Kestler, Bollini, & Hochman, 2004), no studies to date have 
investigated stress as predictor that may relate to racial disparities in functioning in 
schizophrenia. Notably, a few studies have demonstrated a negative relationship between stress 
and functioning among schizophrenia patients (Berger et al., 2018 ; Buonocore et al., 2019 ; 
Yanos & Moos, 2007). Additionally, it is known that Black individuals, as well as other 
racial/ethnic minorities, may be more susceptible to experiencing stress relative to White peers 
due to interpersonal and systemic racism (Berger & Sarnyai, 2015 ; Brown et al., 2020 ; Clark et 
al., 1999). Taken together, these findings imply that exposure to stress may be a particularly 
relevant pathway by which Black Americans with schizophrenia experience poorer outcomes. 
Unfortunately, the current study was unable to assess whether Black participants experienced 
greater exposure to stress compared to Whites and how such differences related to measures of 
functioning, thus this may be a natural next step for future research.  
In regard to the second the aim of this study, it was hypothesized that (a) neurocognition, 
social cognition, and symptom severity would each independently predict participants’ level of 
functioning and (b) the strength of the predictive relationship between these factors and 
functioning would be moderated by participants’ race. One measure of social cognition, the 
AIHQ, predicted functioning as measured by the SLOF, but this relationship was not moderated 
by race. The PANSS total and general symptoms subscale also predicted functioning as 
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measured by the SLOF, and race was found to moderate the relationship between PANSS 
general symptoms and informant-rated functioning measured by the SLOF. These analyses 
indicated that PANSS general symptoms were a significant predictor of informant-rated 
functioning for White participants, but not for Black participants.  
This is the first study to demonstrate that race moderates the relationship between 
symptom severity and functioning among Black and White individuals with schizophrenia, 
which is notable given the strong relationship between symptomatology and functioning (Eack & 
Newhill, 2007 ; Ventura, Hellemann, Thames, Koellner, & Nuechterlein, 2009). Further, this 
finding offers evidence that established predictors of functioning in schizophrenia may not 
operate in the same way across racial lines. However, given that this was the only significant 
moderation by race, the present results largely suggest that the other social cognition and 
symptom variables (i.e., AIHQ, PANSS subscales) predict functional outcomes comparably in 
Black and White individuals.  
It should be noted that significant predictive relationships were not observed between the 
neurocognition social cognition variables, with the exception of the AIHQ, which is in contrast 
to previous studies showing that neurocognition, social cognition are significant predictors of 
functioning outcomes (Fett et al., 2011 ; Halverson, Orleans-Pobee, et al., 2019). Once again, 
how these variables were measured in the present study may offer a potential explanation for 
these null results. For example, neurocognition was assessed using composite scores on the 
RBANS, rather than looking at the individual domains that make up the battery (e.g., immediate 
memory, attention, language, etc.)  Prior studies have found that specific domains of 
neurocognition linked to functioning as measured by the SLOF (Halverson, Orleans-Pobee, et 
al., 2019). Similarly, the use of a social cognition composite may have obscured relationships 
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between the measures of functioning. As previously mentioned, total and composite scores were 
used to reduce Type 1 errors due to multiple comparisons. Nevertheless, these findings, along 
with those of the first aim, ultimately indicate the need to explore other domains that may better 
explain racial disparities in functional outcomes.     
 The final aim of this study was to determine whether there were racial differences in the 
effectiveness of intranasal oxytocin in improving functioning, social cognition, and symptom 
severity among Black and White individuals with schizophrenia. Ultimately, only one measure 
of social cognition, the IPT, and one subscale of symptoms, PANSS positive symptoms, showed 
differences as a function of race and treatment group over time. While Black participants showed 
no significant differences between oxytocin or placebo treatment at any time point, White 
participants in the placebo group exhibited a decrease in positive symptoms relative to White 
participants in the oxytocin group after 6 weeks of treatment. Following a similar trend, White 
participants in the placebo group exhibited improvement on the IPT relative to White 
participants in the oxytocin group after 12 weeks of treatment that bordered on statistical 
significance. As such, the present findings do not offer strong evidence of racial differences in 
the effectiveness of intranasal oxytocin as an adjunctive treatment for schizophrenia. Moreover, 
findings do not suggest that oxytocin significantly improves functioning, social cognition, or 
symptoms for either Black or White individuals with schizophrenia. These findings align with 
previous work, including the parent study from Jarskog et al. (2017), showing limited effects of 
oxytocin on these outcomes in schizophrenia (Halverson, Jarskog, et al., 2019 ; Martins, 
Paduraru, & Paloyelis, 2021).  
Given these results, it is also possible that other domains should be considered when 
investigating the effects of oxytocin among Black individuals with schizophrenia. As previously 
 
 29 
mentioned, stress exposure and reactivity may be an especially important domain to be 
considered in research among Black Americans with schizophrenia. However, a majority of the 
studies investigating the effects of intranasal oxytocin on individuals with schizophrenia have 
primarily focused on oxytocin-induced changes in social cognition and symptomology (Bradley 
& Woolley, 2017 ; Martins et al., 2021). Yet, some existing research offers promising insight 
into how oxytocin may produce more adaptive stress responding in healthy populations (see Olff 
et al., 2013 for a review). For example, studies in nonclinical samples have found that 
participants administered intranasal oxytocin responded to stressors with more adaptive 
physiological reactivity (i.e., reduced cortisol response, more efficient autonomic nervous system 
activity) relative to participants receiving a placebo (Kubzansky, Mendes, Appleton, Block, & 
Adler, 2012 ; Quirin, Kuhl, & Düsing, 2011). If oxytocin is able to produce similar 
enhancements in physiological responses to stress among individuals with schizophrenia, it may 
have important implications for recovery-related outcomes. Given this, future research could 
explore how oxytocin impacts stress-related psychophysiology, which could have indirect effects 
on functioning and recovery in schizophrenia.  
Limitations  
 The current study had a number of limitations that should be considered. First, this study 
utilized a subset of data from a larger double-blind randomized controlled trial on the effects 12 
weeks of daily intranasal oxytocin on treatment outcomes in people with schizophrenia, and 
while the original study was one of the largest oxytocin trials in schizophrenia to 
date, the study was still not adequately powered (Jarskog et al., 2017). This study was similarly 
underpowered given that it used an even smaller sample because some subjects from the overall 
sample were excluded if they did not identify as either Black or White and the sample was also 
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split roughly in half in order to look at group differences by race. Additionally, given the 
extended duration of this study, there was substantial missing data for the longitudinal analyses, 
thus reducing the sample sizes for these analyses as noted in tables 4-6. Due to this small sample 
size and high degree of missing data, the present study should be considered as exploratory. 
Moreover, because this dataset was not collected with the intent to investigate racial differences 
in the domains explored in the present study, other relevant variables that may explain any 
observed differences were not included (e.g., SES, general stress exposure, race-related stress 
exposure, etc.), consequently limiting the ability for a more nuanced investigate of mechanisms 
contributing to racial disparities in schizophrenia. Relatedly, the neurocognitive, social cognitive, 
and symptom measures used in the present have not undergone cross-cultural validation, thus 
complicating interpretations of differences between races, as they may be related to cultural 
differences.  
Conclusion 
 Given the well-documented disparities between Black and White Americans with 
schizophrenia, research exploring pathways through which these disparities manifest is of 
paramount importance. The present study adds to the growing work in this area by highlighting 
the need to investigate additional predictors of functioning beyond neurocognition, social 
cognition, and symptom severity and demonstrating that the relationship between some of these 
established predictors of functioning may vary depending on race. Additionally, this study 
provides evidence that racial differences largely do not exist in the effect of intranasal oxytocin 
on functioning, social cognition, and symptom severity. Future work should seek to continue to 
explore relevant domains in explaining racial differences in schizophrenia outcomes (e.g., SES, 
stress exposure), as well as investigate other extant treatments that may differentially impact 
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Black vs. White Americans with schizophrenia. Research along these lines will be a critical 
steppingstone in addressing the long-standing inequities experienced by Black Americans with 













Table 1. Sociodemographic Characteristics   










Variable   
 
Black  





M (SD) or % (N) 
 N 
 
 N  




38.55 (11.76) 35 41.66 (12.61) 
Gender (male), % (N) 
 
31 70.97 (22) 35 74.29 (26) 
Years of Education, M (SD)* 
 
31 12.23 (1.61) 29 13.66 (1.99) 
Diagnosis, % (N)** 





















Symptom Onset Age, M (SD) 
 
30 22.80 (9.55) 33 21.76 (9.11) 
Duration of Symptoms, M (SD) 
 
30 15.73 (11.70) 33 20.42 (12.40) 
Prior Hospitalizations, M (SD)† 
 
31 4.58 (3.58) 35 9.69 (15.23) 
History of Substance Abuse, % (N) 
 
31 48.57 (13) 35 41.94 (17) 
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Table 2. Baseline Differences in Cognition and Symptom Variables by Race 
aMean and standard error adjusting for group differences in education  
bUnadjusted mean and standard deviation reported 
** p < .01, * p < .05, † p < .10
Variable   
 
Black, M (SE) 
 
 White M (SE) 
 
 N  N  
Neurocognitiona* 
 























Positive Symptoms†  
Negative Symptoms  
General Symptoms  













































Table 3. Bivariate Correlations of Baseline Predictors and Functioning Outcomes 
Abbreviations: SSPA GSS, Social Skills Performance Assessment Global Social Skill; SLOF-I, Specific Levels of Functioning Scale - Informant; SLOF-P, 
SLOF-Participant; AHIQ, Ambiguous Hostile Intentions Questionnaire; PANSS, Positive and Negative Syndrome Scale. 
























RBANS 0.19 0.08 -0.07 1 0.38** 0.12 -0.03 -0.12 -0.12 -0.07 -0.14 





-0.10 -0.02 -0.31* 0.12 -0.07 1 -0.14 0.14 0.04 0.10 0.13 
Trust Task  -0.15 -0.20 0.03 -0.03 -0.22 -0.14 1 -0.03 -0.01 -0.02 -0.03 
PANSS 
General 
-0.19 -0.36* -0.42** -0.12 -0.16 0.14 -0.03 1 0.71** 0.19 0.91** 
PANSS 
Positive  
-0.01 -0.15 -0.23 -0.12 -0.07 0.04 -0.01 0.71** 1 -0.09 0.75** 
PANSS 
Negative 
-0.17 -0.17 -0.20 -0.07 -0.03 0.10 -0.01 0.19 -0.09 1 0.49** 
PANSS 
Total 





Table 4. Change from Baseline for Outcomes of Functioning  
Abbreviations: LS, least squares; SSPA GSS, Social Skills Performance Assessment Global Social Skill; SLOF-I, Specific Levels of Functioning Scale - 
Informant; SLOF-P, SLOF-Participant. All models adjusted for baseline value.  
a Test for within-group change by treatment group within racial group 
b Test for between-group change by treatment group within racial group  
c Test for between-group change by treatmentxrace group 

















 Black White  
































SSPA GSS 12 10 -0.22 (0.15) 0.148 10 -0.03 (0.15) 0.839 0.374 12 -0.03 (0.14) 0.806 13 -0.20 (0.13) 0.143 0.397 0.222 
SLOF-I Total 12 6 1.34 (3.80) 0.729 3 -3.62 (5.55) 0.521 0.469 9 2.26 (3.11) 0.477 8 0.57 (3.30) 0.865 0.712 0.690 
SLOF-P 
Total 






Table 5. Change from Baseline for Outcomes of Social Cognition  
Abbreviations: LS, least squares; AHIQ, Ambiguous Hostile Intentions Questionnaire; ER-40, Penn Emotion Recognition Task; IPT, Interpersonal Perception 
Task. All models adjusted for baseline value. 
a Test for within-group change by treatment group within racial group 
b Test for between-group change by treatment group within racial group  
c Test for between-group change by treatmentxrace group 
** p < .01, * p < .05, † p < .10 
 Black White  








































6 10 1.20 (1.09) 0.279 11 0.76 (1.04) 0.471 0.771 16 -0.14 
(0.87) 
0.877 15 0.23 (0.90) 0.798 0.772 0.681 
 12 10 1.30 (1.09) 0.241 11 -0.61 (1.04) 0.563 0.214 14 -1.44 
(0.90) 
0.118 15 -1.37 
(0.90) 
0.133 0.957 0.321 
ER-40 6 11 0.91 (0.85) 0.288 11 1.84 (0.85) 0.035* 0.446 16 0.98 (0.70) 0.170 15 0.65 (0.74) 0.384 0.748 0.429 
 12 11 -0.27 
(0.85) 
0.755 11 1.38 (0.85) 0.110 0.176 14 0.01 (0.74) 0.989 15 0.71 (0.74) 0.338 0.507 0.556 
Eyes Task 6 11 -0.42 
(0.98) 
0.669 11 -2.89 (0.95) 0.004*
* 
0.074† 16 -0.13 
(0.79) 
0.875 15 -0.10 
(0.82) 
0.905 0.981 0.162 
 12 11 -0.97 
(0.98) 
0.328 11 -1.07 (0.95) 0.267 0.938 14 -0.52 
(0.84) 
0.540 15 0.90 (0.82) 0.280 0.229 0.396 
IPT 6 11 0.24 (0.63) 0.707 10 -1.06 (0.65) 0.113 0.159 16 0.39 (0.52) 0.460 15 0.68 (0.53) 0.210 0.697 0.184 
 12 11 -0.22 
(0.63) 
0.730 10 -1.36 (0.65) 0.043* 0.214 13 -0.70 
(0.57) 
0.228 15 0.81 (0.53) 0.135 0.060† 0.033* 
Trustworthiness 
Task 
6 11 -0.34 
(6.93) 
0.961 11 -13.90 
(6.95) 
0.051* 0.176 16 1.39 (5.72) 0.810 15 4.53 (5.92) 0.448 0.705 0.203 
 12 11 2.75 (6.93) 0.694 11 1.10 (6.95) 0.875 0.868 14 -2.82 
(5.98) 





Table 6. Change from Baseline for Outcomes of Symptoms  
Abbreviations: LS, least squares; PANSS, Positive and Negative Syndrome Scale. All models adjusted for baseline value. 
a Test for within-group change by treatment group within racial group 
b Test for between-group change by treatment group within racial group  
c Test for between-group change by treatmentxrace group 
** p < .01, * p < .05, † p < .10
 Black White  

































6 11 -0.45 (1.44) 0.757 11 -3.00 (1.44) 0.043* 0.218 16 -0.97 (1.20) 0.423 15 -3.62 (1.23) 0.005*
* 
0.129 0.968 
 12 11 -0.72 (1.44) 0.619 11 -3.00 (1.44) 0.043* 0.270 14 -1.58 (1.26) 0.215 15 -2.82 (1.23) 0.0278 0.483 0.703 
PANSS 
Negative 
6 11 -1.05 (1.08) 0.337 11 -0.46 (1.07) 0.670 0.703 16 -1.65 (0.90) 0.072† 15 -0.65 (0.92) 0.486 0.448 0.843 
 12 11 -1.14 (1.08) 0.297 11 -0.37 (1.07) 0.732 0.618 14 -0.74 (0.94) 0.438 15 -1.38 (0.92) 0.141 0.632 0.501 
PANSS 
Positive 
6 11 -1.97 (0.90) 0.033* 11 -0.99 (0.92) 0.286 0.443 16 0.27 (0.75) 0.717 15 -2.46 (0.77) 0.003*
* 
0.014* 0.030* 
 12 11 -2.52 (0.90) 0.007*
* 
11 -0.90 (0.92) 0.332 0.209 14 -0.50 (0.79) 0.533 15 -1.60 (0.77) 0.045* 0.320 0.112 
PANSS 
Total 
6 11 -3.60 (2.58) 0.170 11 -4.22 (2.58) 0.108 0.864 16 -2.21 (2.14) 0.307 15 -7.01 (2.20) 0.003*
* 
0.125 0.385 
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